Evaluation of TMS Visual Outcome
ConditionCataract Surgery Experience
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-80
SponsorShanghai High Myopia Study Group
About this trial
The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients after cataract surgery. The main question it aims to answer is:
• Does TMS improve the visual outcome in patients after cataract surgery? Researchers will compare TMS to the sham-controlled treatment (exposure to recorded sounds of pulses without real magnetic stimulation) to see if TMS works to improve the visual outcomes of patients after cataract surgery.
Participants will
* Undergo TMS treatment or a sham-controlled treatment for consecutive 5 days. * Visit the clinic once every 2 weeks for checkups and tests.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Post cataract surgery
Best-corrected visual acuity less than 0.1logMAR
Disqualifiers
Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment;
Diagnosed with significant opacity of refractive media that affects observation of visual function;
History of epileptic seizures;
Long term use of psychotropic drugs；
Trial design
Design model
Parallel
Treatments tested in this trial
TMS
Procedure/SurgeryTMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
control group
Procedure/SurgeryThe control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: TMSExperimental treatment 1 intervention
Group B: ControlSham comparator 1 intervention
Trial outcomes
Primary outcomes
1
Visual acuity
Time frame
From enrollment to the end of treatment at 2 weeksSecondary outcomes
1
Visual field
Time frame
From enrollment to the end of treatment at 2 weeksOther outcomes
1
Visual quality
Include objective visual quality (contrast sensitivity) and subjective visual quality (visual function questionnaire score).
Time frame
From enrollment to the end of treatment at 12 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: